CD59 Antibodies

Santa Cruz Biotechnology features a diverse variety of CD59 monoclonal antibodies for research focused on understanding this important glycoprotein. CD59 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CD59 is a glycoprotein that plays a critical role in the regulation of the complement system, acting as a protective factor against complement-mediated lysis of cells. CD59 is involved in immune response modulation and has been implicated in various pathological conditions, including cancer and autoimmune diseases. Understanding CD59 function is essential for developing therapeutic strategies targeting complement activation. CD59 monoclonal antibodies enable detailed investigation of cellular and molecular mechanisms in both normal and disease states. CD59 monoclonal antibodies support cutting-edge research in immunology, oncology, and cell biology. Santa Cruz Biotechnology monoclonal antibodies for CD59 contribute to advancing scientific knowledge and therapeutic development across the research community.